ONO-1110 + Placebo

Phase 2Recruiting

1 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Fibromyalgia

Conditions

Fibromyalgia

Trial Timeline

Mar 26, 2025 → Sep 1, 2026

NCT ID

NCT06752590

About ONO-1110 + Placebo

ONO-1110 + Placebo is a phase 2 stage product being developed by Ono Pharmaceutical for Fibromyalgia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06752590. Target conditions include Fibromyalgia.

What happened to similar drugs?

11 of 20 similar drugs in Fibromyalgia were approved

Approved (11) Terminated (3) Active (9)

✅zonisamideEisaiApproved

✅DuloxetineEli LillyApproved

✅duloxetine hydrochloride + placeboEli LillyApproved

✅Duloxetine + PlaceboEli LillyApproved

✅Eszopiclone + placeboSumitomo PharmaApproved

✅QuetiapineAstraZenecaApproved

✅amitriptyline + quetiapineAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06752603	Phase 2	Recruiting	Apr 2, 2025	Aug 1, 2026	Hunner Type Interstitial Cystitis
NCT06752590	Phase 2	Recruiting	Mar 26, 2025	Sep 1, 2026	Fibromyalgia
NCT06708416	Phase 2	Active	Feb 12, 2025	Aug 31, 2026	Postherpetic Neuralgia
NCT06805565	Phase 2	Active	Jan 16, 2025	Oct 31, 2026	Social Anxiety Disorder (SAD)
NCT06792136	Phase 2	Active	Jan 16, 2025	Aug 31, 2026	Major Depressive Disorder (MDD

Competing Products

20 competing products in Fibromyalgia

See all competitors

Product	Company	Stage	Hype Score
DS-5565 + Pregabalin + Placebo tablet + Placebo capsule	Daiichi Sankyo	Phase 3	40
DS-5565	Daiichi Sankyo	Phase 3	40
DS-5565 + Placebo	Daiichi Sankyo	Phase 3	40
DS-5565 + Pregabalin + Placebo tablet + Placebo capsule	Daiichi Sankyo	Phase 3	40
DS-5565 + Pregabalin + Placebo tablet + Placebo capsule	Daiichi Sankyo	Phase 3	40
ASP8062 + Placebo	Astellas Pharma	Phase 2	35
ASP0819 + Placebo	Astellas Pharma	Phase 2	35
Duloxetine	Shionogi	Phase 3	40
Duloxetine 60 mg + Placebo	Shionogi	Phase 3	40
zonisamide	Eisai	Approved	35
Duloxetine	Eli Lilly	Approved	35
duloxetine hydrochloride + placebo	Eli Lilly	Approved	43
duloxetine	Eli Lilly	Phase 3	40
Duloxetine + placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Approved	43
Treatment for Fibromyalgia	Eli Lilly	Pre-clinical	26
Duloxetine + Placebo	Eli Lilly	Phase 3	40
duloxetine + placebo	Eli Lilly	Phase 3	40
Eszopiclone + placebo	Sumitomo Pharma	Approved	43